Bristol-Myers Squibb (NYSE:BMY) Stock Rating Lowered by ValuEngine

ValuEngine lowered shares of Bristol-Myers Squibb (NYSE:BMY) from a sell rating to a strong sell rating in a report released on Thursday, April 4th, ValuEngine reports.

Several other analysts have also issued reports on BMY. BMO Capital Markets restated a buy rating and issued a $60.00 target price on shares of Bristol-Myers Squibb in a research note on Thursday, January 3rd. Bank of America set a $53.00 price target on Bristol-Myers Squibb and gave the company a hold rating in a research report on Friday, January 25th. Zacks Investment Research cut Bristol-Myers Squibb from a buy rating to a hold rating in a research report on Wednesday, January 16th. Morgan Stanley set a $54.00 price target on Bristol-Myers Squibb and gave the company a hold rating in a research report on Thursday, December 20th. Finally, Credit Suisse Group set a $59.00 target price on Bristol-Myers Squibb and gave the stock a hold rating in a research report on Monday, February 4th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and seven have given a buy rating to the company. The stock currently has an average rating of Hold and a consensus target price of $58.50.

Shares of BMY stock traded up $0.25 during trading hours on Thursday, reaching $45.89. The company had a trading volume of 13,563,202 shares, compared to its average volume of 19,743,176. Bristol-Myers Squibb has a 12 month low of $44.30 and a 12 month high of $63.69. The company has a quick ratio of 1.50, a current ratio of 1.61 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $73.57 billion, a PE ratio of 11.53, a P/E/G ratio of 2.33 and a beta of 0.79.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported $1.10 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.09 by $0.01. The company had revenue of $5.92 billion for the quarter, compared to analyst estimates of $5.72 billion. Bristol-Myers Squibb had a return on equity of 48.99% and a net margin of 21.95%. The company’s revenue for the quarter was up 14.0% on a year-over-year basis. During the same quarter last year, the company earned $0.94 earnings per share. On average, equities research analysts anticipate that Bristol-Myers Squibb will post 4.16 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be paid a $0.41 dividend. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $1.64 annualized dividend and a dividend yield of 3.57%. Bristol-Myers Squibb’s payout ratio is currently 41.21%.

Institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc raised its holdings in Bristol-Myers Squibb by 5.9% in the 4th quarter. Legal & General Group Plc now owns 8,568,445 shares of the biopharmaceutical company’s stock worth $445,300,000 after purchasing an additional 474,820 shares during the period. Chescapmanager LLC raised its holdings in Bristol-Myers Squibb by 22.1% in the 4th quarter. Chescapmanager LLC now owns 361,755 shares of the biopharmaceutical company’s stock worth $18,804,000 after purchasing an additional 65,367 shares during the period. Phocas Financial Corp. bought a new position in Bristol-Myers Squibb in the 4th quarter worth $73,000. CSat Investment Advisory L.P. raised its holdings in Bristol-Myers Squibb by 13.6% in the 4th quarter. CSat Investment Advisory L.P. now owns 2,135 shares of the biopharmaceutical company’s stock worth $111,000 after purchasing an additional 255 shares during the period. Finally, Trust Co. of Virginia VA raised its holdings in Bristol-Myers Squibb by 105.7% in the 4th quarter. Trust Co. of Virginia VA now owns 50,048 shares of the biopharmaceutical company’s stock worth $2,601,000 after purchasing an additional 25,712 shares during the period. Institutional investors own 74.09% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

See Also: Stochastic Momentum Index (SMI)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.